Nevertheless, several case reports have suggested that pembrolizumab could trigger immune-related endocrine disorders (5), which may stimulate the production of PTHrP and calcitriol, and potentially cause hypocortisolemia. Here, PTHLH is linked to adrenocortical insufficiency.